☆ 4.8 Letter

Estimation of Eligibility for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Associated Costs Based on the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk) Insights From the Department of Veterans Affairs

CIRCULATION (2017)

Get Full Text
Add to Collection

Journal

CIRCULATION
Volume 135, Issue 25, Pages 2572-2574

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/CIRCULATIONAHA.117.028503

Keywords

cardiovascular disease; cholesterol; lipids

Categories

Cardiac & Cardiovascular Systems Peripheral Vascular Disease

Funding

  1. American Heart Association [14BGIA20460366]
  2. American Diabetes Association Clinical Science and Epidemiology award [1-14-CE-44]
  3. Houston Veteran's Affairs Health Services Research & Development Center for Innovations grant [CIN13-413]

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.